10don MSN
TBRG4 identified as marker of poor survival and driver of tumor progression in lung adenocarcinoma
Lung adenocarcinoma (LUAD) is the most common form of lung cancer, accounting for nearly half of cases. Many patients are ...
The winner of a 2025 SITC grant examines mechanisms that may help explain why drugs that work for some forms of lymphoma ...
Cancer therapies save lives but often cause neurologic damage, so we must recognize the full scope of neurotoxicity, from ...
A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
MedPage Today on MSN
Checkpoint Blockade Finally Breaks Through in Ovarian Cancer
BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...
News-Medical.Net on MSN
Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K–AKT pathway
Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.
News-Medical.Net on MSN
Study finds evidence for repurposing thiostrepton as an anti-rhabdomyosarcoma drug
Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.
The atypical teratoid/rhabdoid tumor market growth is driven by rising molecular diagnosis and increased awareness of this ...
RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback